Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065124 | 0.87 | ALDH1A1 (0.75) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL10340563 | 0.87 | HTT (0.60) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL6052432 | 0.86 | ALDH1A1 (0.59) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL5069717 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL3057553 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL1143334 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL3264275 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL13887595 | 0.84 | NR4A3 (0.72) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL13766911 | 0.84 | HTT (0.58) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL4580685 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2023074847-A1 | NOVEL SPIRO COMPOUND | 田辺三菱製薬株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-10174032-B2 | Heterocyclic compound classes for signaling modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20150315207-A1 | Novel Heterocyclic Compound Classes for Signaling Modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315207-A1 | Novel Heterocyclic Compound Classes for Signaling Modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-4537886-A | β-lactam antibacterial agents and compositions containing them | BEECHAM GROUP P.L.C. (GB) | 1985-08-27 | — | — | US | disclosed |
| EP-0090656-A1 | Penicillins, a process for the preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | ALDH1A1 76/4885HPGD 85/4885SMN1; SMN2 1314/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | ALDH1A1 58/4885HPGD 65/4885SMN1; SMN2 1634/4885 |
| US-20150315207-A1 | Novel Heterocyclic Compound Classes for Signaling Modulation | BRD3, BRPF3, BRD4 | ALDH1A1 4087/4885HPGD 1626/4885SMN1; SMN2 2435/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | ALDH1A1 76/4885HPGD 85/4885SMN1; SMN2 1314/4885 |
| US-10174032-B2 | Heterocyclic compound classes for signaling modulation | BRD3, BRDT, BRPF3 | ALDH1A1 4183/4885HPGD 1659/4885SMN1; SMN2 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.